Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Identifieur interne : 000B48 ( Main/Exploration ); précédent : 000B47; suivant : 000B49Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Auteurs : Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-15.
English descriptors
Abstract
There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22385
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name></author><author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:18CAB01959EC9E2E746617E00BF56310978DC8D2</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22385</idno><idno type="url">https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F25</idno><idno type="wicri:Area/Main/Curation">002B37</idno><idno type="wicri:Area/Main/Exploration">000B48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:regionArea><wicri:noRegion>University of Bremen</wicri:noRegion><wicri:noRegion>University of Bremen</wicri:noRegion></affiliation></author><author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:regionArea><wicri:noRegion>University of Bremen</wicri:noRegion><wicri:noRegion>University of Bremen</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</wicri:regionArea><wicri:noRegion>Charité Universitaetsmedizin Berlin</wicri:noRegion><wicri:noRegion>Charité Universitaetsmedizin Berlin</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15">2009-01-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="133">133</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">18CAB01959EC9E2E746617E00BF56310978DC8D2</idno><idno type="DOI">10.1002/mds.22385</idno><idno type="ArticleID">MDS22385</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>adverse drug reaction reporting systems</term><term>adverse effects</term><term>dopamine agonists</term><term>fibrosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name></noRegion><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:18CAB01959EC9E2E746617E00BF56310978DC8D2
|texte= Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |